Purple Biotech Files 6-K with Purchase Agreement Details

Ticker: PPBT · Form: 6-K · Filed: Dec 4, 2024 · CIK: 1614744

Sentiment: neutral

Topics: disclosure, legal-agreement, financing

TL;DR

Purple Biotech dropped a 6-K detailing a Securities Purchase Agreement and warrants, plus legal opinions.

AI Summary

Purple Biotech Ltd. filed a Form 6-K on December 4, 2024, reporting a Securities Purchase Agreement and related documents. The filing includes exhibits such as the form of the agreement, a placement agent warrant, and legal opinions from FISCHER (FBC & Co.) and Haynes and Boone, LLP.

Why It Matters

This filing provides insight into Purple Biotech's financing activities and legal agreements, which could impact its future operations and investor relations.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of agreements and legal opinions, not indicating immediate operational or financial distress.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing by Purple Biotech Ltd.?

The primary purpose is to report a Securities Purchase Agreement and related documents, including the form of the agreement and a placement agent warrant, as well as legal opinions.

When was this Form 6-K filed with the SEC?

This Form 6-K was filed on December 4, 2024.

Which legal firms provided opinions included in this filing?

FISCHER (FBC & Co.) and Haynes and Boone, LLP provided legal opinions.

What is Purple Biotech Ltd.'s former company name mentioned in the filing?

Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.

What is the business address of Purple Biotech Ltd. as listed in the filing?

The business address is 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.

Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 15.1 · Accepted 2024-12-04 11:40:33

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. December 4, 2024 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing